Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Backs Mylan’s REMS Antitrust Lawsuit Against Celgene

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.

Advertisement

Related Content

Will FTC Shakeup Impact Pharma?
REMS Class-Action Lawsuit Against Celgene Is First By Patients
REMS Class-Action Lawsuit Against Celgene Is First By Patients
Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC
Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC
REMS Abuses: Congressional Panel’s Focus Turns To Federal Trade Commission
Safety Trolls?: Generic Firms Seek To Invalidate Xyrem REMS Patent Via PTO
Brand, Generic Disputes Over Access Move Beyond REMS Restrictions
REMS Hurdles To Generic Entry: From Brand Access To Patent Claims
Playing It Too Safe?: FTC Investigating Use Of REMS To Block Generics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel